New drug combo aims to shrink tumors before surgery
NCT ID NCT07493382
Summary
This study is testing whether adding a new immunotherapy drug (Retlirafusp alfa) to standard chemotherapy helps people with a type of stomach cancer where the stomach meets the esophagus. The goal is to shrink the tumor before surgery and then use the new drug after surgery to try to keep the cancer from coming back. The study will enroll 30 adults who have not had prior cancer treatment to see if the combination is safe and effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEJ ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.